SynthesisF1000Research2025
Examining Differences in Pathological Outcomes and Safety for Prostate Cancer Patients Undergoing Either Subcapsular Orchiectomy or Medical Androgen Deprivation Therapy: A Systematic Review.
Synthesis in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this systematic review is to investigate differences in pathological outcomes and safety between subcapsular orchiectomy and pharmacological androgen deprivation therapy (ADT) for prostate cancer management. Methods: A systematic search was conducted on PubMed, Google Scholar, and ScienceDirect for original articles published until February 2024 that compared tumour characteristics, biochemical markers, and adverse effects associated with these treatments. The risk of bias from each study was assessed using the Newcastle Ottawa Scale and Risk of Bias-2 (ROB-2) tool. Results: Eleven studies meeting the inclusion criteria were analysed. Both subcapsular orchiectomy and pharmacological ADT effectively reduced tumour size and prostate-specific antigen (PSA) levels. Subcapsular orchiectomy was linked to higher surgical complication rates. At the same time, due to its systemic pharmacological mechanisms, pharmacological ADT carries a greater risk of metabolic side effects, such as weight gain and insulin resistance. Conclusions: Both subcapsular orchiectomy and pharmacological ADT are viable options for prostate cancer treatment. However, their differing safety and pharmacological profiles highlight the need for personalised treatment strategies based on individual patient factors and preferences. PROSPERO registration: CRD42025634678 (17/01/2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.